Comparative Effectiveness, Generic Biologics Draw Insurers’ Lobbying Efforts
Executive Summary
Comparative effectiveness research and generic biologics are among the key pharmaceutical issues that attracted lobbying efforts by large health insurers in the first half of 2007, according to reports filed recently with Congress
You may also be interested in...
New Comparative Effectiveness Center Should Ensure Evidence Quality – IOM
The Institute of Medicine says the government can boost the quality and usefulness of comparative effectiveness research by creating a single national program to build on existing efforts
New Comparative Effectiveness Center Should Ensure Evidence Quality – IOM
The Institute of Medicine says the government can boost the quality and usefulness of comparative effectiveness research by creating a single national program to build on existing efforts
Drug Industry Boosts Lobbying Coffers; Amgen Doubles Its Expenditures
Lobbyists for the pharmaceutical industry have had plenty of work this year as Congress pushed forward legislation to overhaul the patent system, mandate lower drug prices for Medicare, and clear the way for approval of generic biologics